Views

CrossRef citations to date

Altmetric

Research Article

Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response

AJ Mathew1 Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics Rigshospitalet, Glostrup, Denmark;2 Department of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, IndiaCorrespondence[email protected]

https://orcid.org/0000-0002-2061-2042 View further author information

M. L. Lund1 Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics Rigshospitalet, Glostrup, Denmark;3 The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark;4 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkView further author information

MP Pedersen1 Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics Rigshospitalet, Glostrup, DenmarkView further author information

SH Rasmussen1 Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics Rigshospitalet, Glostrup, DenmarkView further author information

B Glintborg1 Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics Rigshospitalet, Glostrup, Denmark;3 The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark;4 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkView further author information

AG Loft3 The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark;5 Department of Rheumatology, Aarhus University Hospital, Aarhus, DenmarkView further author information

MJ Nissen6 Department of Rheumatology, Geneva University Hospital, Geneva, SwitzerlandView further author information

B Möller7 Department of Rheumatology and Immunology, Inselspital – University Hospital Bern, University of Bern, Bern, SwitzerlandView further author information

AM Rodrigues8 Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal;9 EpiDoC Unit, CEDOC, Nova Medical School, Lisbon, Portugal;10 Rheumatology Unit, Hospital dos Lusíadas, Lisbon, PortugalView further author information

FP Santos8 Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal;10 Rheumatology Unit, Hospital dos Lusíadas, Lisbon, Portugal;11 Rheumatic Diseases Lab, NOVA Medical School, NOVA University of Lisbon, Lisbon, PortugalView further author information

Z Rotar12 biorx.si and Department of Rheumatology, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, SloveniaView further author information

M Tomšič12 biorx.si and Department of Rheumatology, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, SloveniaView further author information

H Relas13 Inflammation Center, Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, FinlandView further author information

R Peltomaa13 Inflammation Center, Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, FinlandView further author information

B Gudbjornsson14 Centre for Rheumatology Research (ICEBIO), University Hospital, and Faculty of Medicine, University of Iceland, Reykjavik, IcelandView further author information

TJ Löve15 Department of Internal Medicine, Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, TurkeyView further author information

SB Kocaer16 Faculty of Medicine, and Landspitali University Hospital, University of Iceland, Reykjavik, IcelandView further author information

A Koken Avsar17 Department of Rheumatology, Kocaeli Public Hospital, Kocaeli, TurkeyView further author information

L Midtbøll Ørnbjerg1 Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics Rigshospitalet, Glostrup, DenmarkView further author information

M Østergaard1 Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics Rigshospitalet, Glostrup, Denmark;3 The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark;4 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkView further author information

show all

Figures & data

Figure 1. Distribution of enthesitis among patients evaluated with SPARCC and MASES at the initiation of the first tumour necrosis factor inhibitor (TNFi). SPARCC, Spondyloarthritis Research Consortium of Canada enthesitis scoring system; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score. The colours of the circles indicate the proportion (percentage) of examined entheses with enthesitis at the initiation of the first TNFi. The letters in the circles refer to the individual entheses.

Table 1. Patient characteristics, disease activity measures, and patient-reported outcomes at initiation of the first tumour necrosis factor inhibitor (TNFi-1) in the cohort stratified by MASES and SPARCC scores.

Download CSV Display Table

Table

Download CSV Display Table

Table 2. Distribution of enthesitis by MASES and SPARCC scoring systems among all patients at the initiation of the first tumour necrosis factor inhibitor (TNFi-1).

Download CSV Display Table

Table 4. Linear regression models for association between clinical variables and patient-reported outcomes with enthesitis scores at baseline.

Download CSV Display Table

Table 3. Effectiveness of the first tumour necrosis factor inhibitor (TNFi) evaluated as change in MASES and SPARCC scores and resolution of enthesitis at follow-up.

Download CSV Display Table

Supplemental material

Supplemental Material

Download MS Word (65.8 KB)

Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response

Table 1. Patient characteristics, disease activity measures, and patient-reported outcomes at initiation of the first tumour necrosis factor inhibitor (TNFi-1) in the cohort stratified by MASES and SPARCC scores.

Table 2. Distribution of enthesitis by MASES and SPARCC scoring systems among all patients at the initiation of the first tumour necrosis factor inhibitor (TNFi-1).

Table 4. Linear regression models for association between clinical variables and patient-reported outcomes with enthesitis scores at baseline.

Table 3. Effectiveness of the first tumour necrosis factor inhibitor (TNFi) evaluated as change in MASES and SPARCC scores and resolution of enthesitis at follow-up.

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response

Figures & data

Table 1. Patient characteristics, disease activity measures, and patient-reported outcomes at initiation of the first tumour necrosis factor inhibitor (TNFi-1) in the cohort stratified by MASES and SPARCC scores.

Table 2. Distribution of enthesitis by MASES and SPARCC scoring systems among all patients at the initiation of the first tumour necrosis factor inhibitor (TNFi-1).

Table 4. Linear regression models for association between clinical variables and patient-reported outcomes with enthesitis scores at baseline.

Table 3. Effectiveness of the first tumour necrosis factor inhibitor (TNFi) evaluated as change in MASES and SPARCC scores and resolution of enthesitis at follow-up.

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date